A5329: Interferon –Free Therapy for Chronic Hepatitis C Virus Genotype 1 infection in persons with HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy: A5334s Pharmacokinetic Substudy

Study Location:

Baltimore

Topic:

Hepatitis and HIV

Clinicaltrials.gov Link:

https://clinicaltrials.gov/ct2/show/NCT02194998?term=a5329&rank=1

IRB#:

Pro00010596

Coordinator:

Anna Wimpelberg (Washington)

​Ilene Wiggins, RN (Baltimore)
 

Enrollment:

Closed

Trial Period:

Ongoing

A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C medications.  New “direct acting antiviral” drugs (DAAs) ABT-450/r/ABT-267 plus ABT-333 will be tested as part of a drug regimen that does not contain the drug interferon for either 24 or 12 weeks of treatment. 

  • HIV and Hepatitis C co-infected people 18 to 70 years old
  • HIV viral load less than 50 copies
  • Currently on one of the following HIV regimens:  
    • raltegravir or darunavir/ritonavir  AND tenofovir plus FTC or 3TC
  • No history of resistance or failure of anti-HIV therapy
  • CD4 count greater than 200
  • No prior HCV treatment
  • HCV viral load greater than 10,000
  • HCV genotype 1

Anna Wimpelberg (Washington)
202-797-3589
awimpelberg@whitman-walker.org


​Ilene Wiggins, RN (Baltimore)
410-614-2766
iwiggin1@jhmi.edu

Categories

Location
Topic

Clinical Trials

A5279, Phase III Clinical Trial of Ultra-Short-Course...

This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...

Read More

P1060:  Phase II, parallel, randomized, clinical trials...

A single dose of nevirapine (SD NVP) given to an HIV infected pregnant woman followed by a single dose to her infant has been...

Read More

A5290, A Randomized, Phase 2b Study of a Double-Dose...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Read More

A5361s: Pitavastatin to REduce Physical Function Impairment...

A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...

Read More

P1077FF: Formula Feeding Version of the PROMISE Study...

1077FF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More